- Home
- JBGS vs CDNA Comparison
JBGS vs CDNA Comparison
Compare JBGS & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JBGS
- CDNA
- Stock Information
- Founded
- JBGS 2016
- CDNA 1998
- Country
- JBGS United States
- CDNA United States
- Employees
- JBGS N/A
- CDNA N/A
- Industry
- JBGS Real Estate Investment Trusts
- CDNA Medical Specialities
- Sector
- JBGS Real Estate
- CDNA Health Care
- Exchange
- JBGS Nasdaq
- CDNA Nasdaq
- Market Cap
- JBGS 1.3B
- CDNA 1.1B
- IPO Year
- JBGS 2017
- CDNA 2014
- Fundamental
- Price
- JBGS $16.12
- CDNA $17.75
- Analyst Decision
- JBGS Sell
- CDNA Buy
- Analyst Count
- JBGS 2
- CDNA 8
- Target Price
- JBGS $16.00
- CDNA $29.43
- AVG Volume (30 Days)
- JBGS 1.2M
- CDNA 673.3K
- Earning Date
- JBGS 04-29-2025
- CDNA 05-08-2025
- Dividend Yield
- JBGS 4.32%
- CDNA N/A
- EPS Growth
- JBGS N/A
- CDNA N/A
- EPS
- JBGS N/A
- CDNA 0.93
- Revenue
- JBGS $546,890,000.00
- CDNA $333,785,000.00
- Revenue This Year
- JBGS N/A
- CDNA $13.32
- Revenue Next Year
- JBGS $7.15
- CDNA $14.99
- P/E Ratio
- JBGS N/A
- CDNA $19.11
- Revenue Growth
- JBGS N/A
- CDNA 19.07
- 52 Week Low
- JBGS $13.65
- CDNA $7.42
- 52 Week High
- JBGS $18.86
- CDNA $34.84
- Technical
- Relative Strength Index (RSI)
- JBGS 60.29
- CDNA 37.14
- Support Level
- JBGS $15.74
- CDNA $18.16
- Resistance Level
- JBGS $16.12
- CDNA $20.00
- Average True Range (ATR)
- JBGS 0.51
- CDNA 0.83
- MACD
- JBGS 0.11
- CDNA 0.02
- Stochastic Oscillator
- JBGS 93.11
- CDNA 23.73
About JBGS JBG SMITH Properties
JBG SMITH Properties is a real estate investment trust based in the United States. It owns, operates, invests in and develops real estate assets concentrated in urban infill submarkets in and around Washington, DC. In addition, the company also provides fee-based real estate services to the legacy funds through its third-party real estate services business. The operating segments of the company are commercial, multifamily and third-party asset management and real estate services. The company generates majority of its revenue from Commercial segment.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.